Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis

被引:66
作者
Ailawadhi, Sikander [1 ]
Frank, Ryan D. [2 ]
Advani, Pooja [1 ]
Swaika, Abhisek [1 ]
Temkit, M'hamed [3 ]
Menghani, Richa [1 ]
Sharma, Mayank [1 ]
Meghji, Zahara [1 ]
Paulus, Shumail [1 ]
Khera, Nandita [4 ]
Hashmi, Shahrukh K. [5 ]
Paulus, Aneel [1 ]
Kakar, Tanya S. [1 ]
Hodge, David O. [2 ]
Colibaseanu, Dorin T. [6 ]
Vizzini, Michael R. [7 ]
Roy, Vivek [1 ]
Colon-Otero, Gerardo [1 ]
Chanan-Khan, Asher A. [1 ]
机构
[1] Mayo Clin, Div Hematol & Med Oncol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA
[2] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA
[3] Mayo Clin, Div Biomed Stat, Scottsdale, AZ USA
[4] Mayo Clin, Div Hematol & Med Oncol, Scottsdale, AZ USA
[5] Mayo Clin, Div Hematol, Rochester, MN USA
[6] Mayo Clin, Colon & Rectal Surg, Jacksonville, FL 32224 USA
[7] Mayo Clin, Florida Adm, Jacksonville, FL 32224 USA
关键词
Cancer management; HEMATOPOIETIC-CELL TRANSPLANTATION; RENAL-FAILURE; CANCER; OUTCOMES; SURVIVAL; IMPACT; BORTEZOMIB; MANAGEMENT; ACCESS;
D O I
10.1002/cam4.1246
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Outcomes have improved considerably in multiple myeloma (MM), but disparities among racial-ethnic groups exist. Differences in utilization of novel therapeutics are likely contributing factors. We explored such differences from the SEER-Medicare database. A utilization analysis of lenalidomide, thalidomide, bortezomib, and stem cell transplant (SCT) was performed for patients diagnosed with MM between 2007 and 2009, including use over time, use by race, time-dependent trends for each racial subgroup, and survival analysis. A total of 5338 MM patients were included with median 2.4-year follow-up. Within the first year of MM diagnosis, utilization of lenalidomide, bortezomib, SCT, and more than one novel agent increased over time while utilization of thalidomide decreased. There was significantly lower utilization of lenalidomide among African-Americans (P<0.01), higher thalidomide use among Hispanics and Asians (P<0.01), and lower bortezomib use among Asians (P<0.01). Hispanics had the highest median number of days to first dose of bortezomib (P=0.02) and the lowest utilization of SCT (P<0.01). Hispanics and Asians were the only groups without notable increases in lenalidomide and bortezomib use, respectively. SCT utilization increased over time for all except African-Americans. SCT use within the first year after diagnosis was associated with better overall survival (HR 0.52; 95% CI: 0.4-0.68), while bortezomib use was associated with inferior survival (HR 1.14; 95% CI 1.02-1.28). We noted considerable variability in MM therapeutics utilization with seeming inequity for racial-ethnic minorities. These trends should be considered to eliminate drug access and utilization disparities and achieve equitable benefit of therapeutic advances across all races.
引用
收藏
页码:2876 / 2885
页数:10
相关论文
共 33 条
[1]   Disparities in treatment patterns and outcomes between Caucasian and African American patients with multiple myeloma (MM). [J].
Abouzaid, Safiya ;
Parikh, Kejal ;
Zhou, Zheng-Yi ;
Zhou, Zhou ;
Tang, Wenxi ;
Xie, Jipan ;
Patel, Manali I. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2]   Trends in Disease Presentation, Management, Cost of Care and Outcomes: A Comprehensive Look at Racial Disparities in Multiple Myeloma (MM) [J].
Ailawadhi, Sikander ;
Frank, Ryan D. ;
Sharma, Mayank ;
Menghani, Richa ;
Temkit, M'hamed ;
Paulus, Shumail M. ;
Khera, Nandita ;
Hashmi, Shahrukh K. ;
Advani, Pooja ;
Swaika, Abhisek ;
Paulus, Aneel ;
Aslam, Nabeel ;
Roy, Vivek ;
Colon-Otero, Gerardo ;
Chanan-Khan, Asher A. .
BLOOD, 2016, 128 (22)
[3]   Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis [J].
Ailawadhi, Sikander ;
Advani, Pooja ;
Yang, Dongyun ;
Ghosh, Radhika ;
Swaika, Abhisek ;
Roy, Vivek ;
Foran, James ;
Colon-Otero, Gerardo ;
Chanan-Khan, Asher .
CANCER, 2016, 122 (04) :618-625
[4]   Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups [J].
Ailawadhi, Sikander ;
Aldoss, Ibrahim T. ;
Yang, Dongyun ;
Razavi, Pedram ;
Cozen, Wendy ;
Sher, Taimur ;
Chanan-Khan, Asher .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (01) :91-98
[5]   Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents [J].
Al-Hamadani, Mohammed ;
Hashmi, Shahrukh K. ;
Go, Ronald S. .
AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (08) :825-830
[6]   Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology Group [J].
Albain, Kathy S. ;
Unger, Joseph M. ;
Crowley, John J. ;
Coltman, Charles A., Jr. ;
Hershman, Dawn L. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (14) :984-992
[7]  
[Anonymous], SEER MEDICARE MEDICA
[8]  
[Anonymous], NAACCR GUID ENH HISP
[9]   Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study [J].
Chanan-Khan, Asher A. ;
Kaufman, Jonathan L. ;
Mehta, Jayesh ;
Richardson, Paul G. ;
Miller, Kena C. ;
Lonial, Sagar ;
Munshi, Nikhil C. ;
Schlossman, Robert ;
Tariman, Joseph ;
Singhal, Seema .
BLOOD, 2007, 109 (06) :2604-2606
[10]   Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma [J].
Costa, Luciano J. ;
Huang, Jia-Xing ;
Hari, Parameswaran N. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (04) :701-706